-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since October, listed companies have entered a period of intensive disclosure of third quarter reports
.
According to the data, as of October 7, 117 companies have issued performance forecasts for the first three quarters of 2021.
96 companies are expected to increase their net profit attributable to their parent companies, accounting for more than 80%, and 50 companies are expected to increase their net profits as high as Above 100%
.
Judging from the pre-happy industries, they are mainly concentrated in the chemical, electronics, medical and biological, light industrial manufacturing and other industries
.
Among them, in the field of medicine and biology, Yan'an Bikang is the performance "pre-increasing king".
The company expects to achieve a net profit of 550 million yuan to 600 million yuan in the first three quarters, a year-on-year increase of 4207.
51%-4599.
1%
.
It is understood that there are two main factors driving the growth of Yanan Bikang’s performance: First, the new energy products of Jiujiujiu Technology, a subsidiary of Yan’an Bikang, are affected by market demand, the release of production capacity, and the increase in market prices, resulting in profit compared with last year.
Increase in the same period; due to the release of production capacity and other reasons, the profit of the new materials sector also increased compared with the same period last year
.
Second, in accordance with relevant investment promotion policies, the Administrative Committee of Jiangsu Xinyi Economic Development Zone should subsidize Jiaan Health, a subsidiary of Yan'an Bikang, for 113 million yuan
.
Jiaan Health received a subsidy of 92.
31 million yuan in the first quarter of this year
.
It is worth mentioning that while the performance has increased significantly, the company's stock price has performed well
.
Yan'an Bikang's share price ushered in a significant rise in the third quarter, with a range increase of 213%
.
In recent days, a number of pharmaceutical companies have disclosed their announcements on pre-increasing results for the first three quarters of 2021
.
Among them, Proton announced on October 11 that the net profit for the first three quarters is expected to be 347 million yuan-370 million yuan, a year-on-year increase of 45%-55%
.
Proton covers three major business segments: "API CDMO", "Preparation CDMO", and "Gene Cell Therapy CDMO"
.
The announcement shows that in the third quarter of 2021, the company's preparations CDMO and gene cell therapy CDMO are still at a loss stage, and the total net profit attributable to shareholders of listed companies in the company's consolidated statement will be reduced by approximately 25 million yuan; the total decrease in the first three quarters The net profit attributable to shareholders of the listed company in the company’s consolidated statement is approximately 71 million yuan
.
In addition, Huaren Pharmaceutical disclosed its performance forecast on the evening of October 8.
It is expected that the net profit attributable to shareholders of listed companies in the first three quarters of 2021 will be 105 million to 125 million yuan, an increase of 94.
09%-131.
06% over the same period of the previous year
.
Regarding the growth in performance, the company stated that with the effective control of the domestic epidemic, the company continues to improve sales channels, open up incremental markets, fill in blank areas, strengthen market access, and actively respond to the national, provincial, and municipal three-level centralized procurement Policy, drug sales have increased compared with the same period last year
.
Of course, in addition to companies that report good performance in the third quarter, there are also early warnings of the third quarter reports of many pharmaceutical companies
.
Among them, Haixiang Pharmaceutical expects that its performance in the first three quarters will drop by more than 50%
.
The company said that the main factors for the year-on-year decline in net profit were: the large amortization amount of the employee stock ownership plan; the increase in raw material prices and the impact of exchange rate fluctuations; and the decrease in capacity utilization compared with the same period last year
.
However, the company also stated that it has focused on optimizing the industrial chain and core intermediate production capacity layout to consolidate the product foundation.
The capacity utilization rate will rebound in the third quarter of 2021, and profitability will gradually improve
.
In addition, Shanghai Yizhong is expected to lose 25 million yuan to 22 million yuan
.
It is understood that the company has been engaged in drug research and development since its establishment.
During the reporting period, the company was still in the drug research and development stage and had no actual sales.
The continuous R&D investment resulted in negative net profits during the reporting period
.
.
According to the data, as of October 7, 117 companies have issued performance forecasts for the first three quarters of 2021.
96 companies are expected to increase their net profit attributable to their parent companies, accounting for more than 80%, and 50 companies are expected to increase their net profits as high as Above 100%
.
Judging from the pre-happy industries, they are mainly concentrated in the chemical, electronics, medical and biological, light industrial manufacturing and other industries
.
Among them, in the field of medicine and biology, Yan'an Bikang is the performance "pre-increasing king".
The company expects to achieve a net profit of 550 million yuan to 600 million yuan in the first three quarters, a year-on-year increase of 4207.
51%-4599.
1%
.
It is understood that there are two main factors driving the growth of Yanan Bikang’s performance: First, the new energy products of Jiujiujiu Technology, a subsidiary of Yan’an Bikang, are affected by market demand, the release of production capacity, and the increase in market prices, resulting in profit compared with last year.
Increase in the same period; due to the release of production capacity and other reasons, the profit of the new materials sector also increased compared with the same period last year
.
Second, in accordance with relevant investment promotion policies, the Administrative Committee of Jiangsu Xinyi Economic Development Zone should subsidize Jiaan Health, a subsidiary of Yan'an Bikang, for 113 million yuan
.
Jiaan Health received a subsidy of 92.
31 million yuan in the first quarter of this year
.
It is worth mentioning that while the performance has increased significantly, the company's stock price has performed well
.
Yan'an Bikang's share price ushered in a significant rise in the third quarter, with a range increase of 213%
.
In recent days, a number of pharmaceutical companies have disclosed their announcements on pre-increasing results for the first three quarters of 2021
.
Among them, Proton announced on October 11 that the net profit for the first three quarters is expected to be 347 million yuan-370 million yuan, a year-on-year increase of 45%-55%
.
Proton covers three major business segments: "API CDMO", "Preparation CDMO", and "Gene Cell Therapy CDMO"
.
The announcement shows that in the third quarter of 2021, the company's preparations CDMO and gene cell therapy CDMO are still at a loss stage, and the total net profit attributable to shareholders of listed companies in the company's consolidated statement will be reduced by approximately 25 million yuan; the total decrease in the first three quarters The net profit attributable to shareholders of the listed company in the company’s consolidated statement is approximately 71 million yuan
.
In addition, Huaren Pharmaceutical disclosed its performance forecast on the evening of October 8.
It is expected that the net profit attributable to shareholders of listed companies in the first three quarters of 2021 will be 105 million to 125 million yuan, an increase of 94.
09%-131.
06% over the same period of the previous year
.
Regarding the growth in performance, the company stated that with the effective control of the domestic epidemic, the company continues to improve sales channels, open up incremental markets, fill in blank areas, strengthen market access, and actively respond to the national, provincial, and municipal three-level centralized procurement Policy, drug sales have increased compared with the same period last year
.
Of course, in addition to companies that report good performance in the third quarter, there are also early warnings of the third quarter reports of many pharmaceutical companies
.
Among them, Haixiang Pharmaceutical expects that its performance in the first three quarters will drop by more than 50%
.
The company said that the main factors for the year-on-year decline in net profit were: the large amortization amount of the employee stock ownership plan; the increase in raw material prices and the impact of exchange rate fluctuations; and the decrease in capacity utilization compared with the same period last year
.
However, the company also stated that it has focused on optimizing the industrial chain and core intermediate production capacity layout to consolidate the product foundation.
The capacity utilization rate will rebound in the third quarter of 2021, and profitability will gradually improve
.
In addition, Shanghai Yizhong is expected to lose 25 million yuan to 22 million yuan
.
It is understood that the company has been engaged in drug research and development since its establishment.
During the reporting period, the company was still in the drug research and development stage and had no actual sales.
The continuous R&D investment resulted in negative net profits during the reporting period
.
